CytomX Therapeutics (NASDAQ:CTMX) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $(0.06) by 383.33 percent. The company reported quarterly sales of $41.463 million which beat the analyst consensus estimate of $21.434 million by 93.44 percent. This is a 76.45 percent increase over sales of $23.499 million the same period last year.
CytomX Therapeutics Q1 2024 GAAP EPS $0.17 Beats $(0.06) Estimate, Sales $41.463M Beat $21.434M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.